Personal Genetics Education Project

In the News: Clinical use of CRISPR takes a step forward

This week, the Recombinant DNA Research Advisory Committee, an advisory body to the US National Institutes of Health, gave its go-ahead to the first clinical trial of the gene editing tool CRISPR-Cas9 in humans. While the trial must still be approved by the Food and Drug Administration and other ethics review bodies, it represents another major milestone in the rapid progress of gene editing technologies towards clinical application.

The proposed therapy uses CRISPR to edit immune cells taken from cancer patients, which are then infused back into the patients with the hope that the edited immune cells will destroy the patients’ cancer cells — a personalized medical treatment called “immunotherapy”. While this clinical trial, if eventually approved, would be the first use of CRISPR in humans, immunotherapy trials making use of other gene editing tools are in progress — a hospital in the UK used a molecular tool called TALENs to treat a baby girl with leukemia last year, and a clinical trial for that particular therapy officially started last week.

While promising, the clinical use of CRISPR, which has garnered much attention in the past couple of years for making it dramatically easier to alter DNA, still faces a few technical hurdles. Another source of concern is the affordability of such a therapy. Treatments that make use of gene editing fall into the broader category of “gene therapies”, which aim to treat diseases at the genetic level by, e.g., replacing a non-functioning copy of a gene with a functional one. While no gene therapies have yet been approved in the US, two therapies are approved in Europe, including one approved at the end of May for the “bubble boy” disease. However, such treatments can cost as much as a million dollars per person, which would put them out of reach for many patients. To maximize the health impact of these potentially life-saving therapies would require finding solutions to address the issue of cost.

immunotherapy

Immune cells (red) attacking cancer cell.

Image credit: National Cancer Institute \ Duncan Comprehensive Cancer Center at Baylor College of Medicine (CC BY 2.0)

Upcoming Events

Sep 14

National Society of Genetic Counselors annual conference

September 14
Columbus OH
United States
Sep 15

Duke panel on Orphan Black

September 15
Durham NC
United States
Nov 09

National Association of Biology Teachers annual conference

November 9 - November 12
Saint Louis MO
United States

In the News

As we finish up another week of Teaching the Genome Generation at the Jackson Lab in Bar Harbor Maine, teachers are excited to receive a copy of David Epstein's "The Sports Gene". pgEd loves leading the social and ethical dimension of this annual professional development course. Looking for some summer reading? Check out pged.org/book-corner/ ... See MoreSee Less

Posted by pgEd 2 weeks ago

As we finish up another week of Teaching the Genome Generation at the Jackson Lab in Bar Harbor Maine, teachers are excited to receive a copy of David Epsteins The Sports Gene. pgEd loves leading the social and ethical dimension of this annual professional development course.  Looking for some summer reading? Check out http://pged.org/book-corner/

What a wonderful three days at our Summer Institute! Thanks to our friends at Brockton High School for hosting us, and to all the teachers who came and shared their energy, passion and ideas. There will be lots for pgEd to get inspirations from as we develop our new unit of lessons on genetics and identity.
See everyone at our next workshop in Boston in less than two weeks!
... See MoreSee Less

Posted by pgEd 4 weeks ago

What a wonderful three days at our Summer Institute! Thanks to our friends at Brockton High School for hosting us, and to all the teachers who came and shared their energy, passion and ideas. There will be lots for pgEd to get inspirations from as we develop our new unit of lessons on genetics and identity.
See everyone at our next workshop in Boston in less than two weeks!

Sign Up For Our Newsletter